Warenkorb
Kostenloser Versand
Unsere Operationen sind klimaneutral

SITCs Guide to Managing Immunotherapy Toxicity Marc Ernstoff

SITCs Guide to Managing Immunotherapy Toxicity von Marc Ernstoff

SITCs Guide to Managing Immunotherapy Toxicity Marc Ernstoff


€12.49
Zustand - Gut
Nur noch 1

Zusammenfassung

A practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Part One contains chapter-based overviews of immune checkpoint inhibitors in the clinic. Part Two is structured by common and uncommon toxicities that affect major organ sites throughout the body.

SITCs Guide to Managing Immunotherapy Toxicity Zusammenfassung

SITCs Guide to Managing Immunotherapy Toxicity Marc Ernstoff

The Society for Immunotherapy of Cancer's handbook,SITCs Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer

Inhaltsverzeichnis

Foreword Introduction Part 1: Immune Checkpoint Inhibitors in the Clinic Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab Daniel Hartman Johnson and Jianjun Gao Chapter Two: Overview of PD-1 and PD-L1 Inhibitors Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor Combinations Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber Part 2: Specific Immune Checkpoint Inhibitor Toxicities Chapter Four: General Principles of Immune-Related Toxicities Osama E. Rahma and Patrick A. Ott Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus Jennifer Wu and Mario E. Lacouture Chapter Six: Musculoskeletal and Rheumatologic Toxicities Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor Chapter Seven: Immune-Related Gastrointestinal Toxicities Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades Vickie R. Shannon Chapter Nine: Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors Rajeev Sharma, Ha Nguyen, Ramona Dadu Chapter Ten: Neurologic Adverse Events and Neurologic Complications Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors Pankit Vachhani, Igor Puzanov, Javid J. Moslehi Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint Inhibitors Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins George L. Chen, Caroline Robert, Alexander M. Lesokhin Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation Liliya Golas and Dimitra Skondra Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy Eric D. Hansen, Michelle Walter, Amy A. Case Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer Therapies Christine Kohn, Natalia Shcherbakova, Alberto J. Montero

Zusätzliche Informationen

GOR013964381
9780826172143
0826172148
SITCs Guide to Managing Immunotherapy Toxicity Marc Ernstoff
Gebraucht - Gut
Broschiert
Springer Publishing Co Inc
2019-03-20
274
N/A
Die Abbildung des Buches dient nur Illustrationszwecken, die tatsächliche Bindung, das Cover und die Auflage können sich davon unterscheiden.
Dies ist ein gebrauchtes Buch. Es wurde schon einmal gelesen und weist von der früheren Nutzung Gebrauchsspuren auf. Wir gehen davon aus, dass es im Großen und Ganzen in einem guten Zustand ist. Sollten Sie jedoch nicht vollständig zufrieden sein, setzen Sie sich bitte mit uns in Verbindung.